BridgeBio Pharma, Inc. — Form SCHEDULE 13D/A
Filed July 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Opportunities Fund (reporting person) sold 1,282,892 shares of BridgeBio common stock between May 22 and July 9, 2026, at prices ranging from $66.09 to $90.40 per share. Total sale proceeds approximately $90.8M. All transactions executed in open market through broker.
Why this rating
Large absolute dollar amount (~$91M) but modest relative to $7.3B market cap (~1.2%). Standard insider/large shareholder divestment over extended period; no control shift or strategic change signaled.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.